Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival versus placebo. Here, we report prespecified, investigator-assessed, exploratory post-progression endpoints and updated safety data. In this ongoing (enrolment complete) randomised, placebo-controlled, phase...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2020-05, Vol.21 (5), p.710-722
Hauptverfasser:	Ledermann, Jonathan A, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew R, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M, Cameron, Terri, Maloney, Lara, Goble, Sandra, Coleman, Robert L
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Cancer therapies Carcinoma - drug therapy Carcinoma - pathology Chemotherapy Clinical trials Disease Progression Double-Blind Method Fallopian tube Fallopian tubes Female Genital cancers Gynecological cancer Hemoglobin Homologous recombination Homologous recombination repair Humans Indoles - administration & dosage Indoles - adverse effects Middle Aged Mutation Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Oncology Ovarian cancer Ovarian carcinoma Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Patients Peritoneum Platinum Platinum - administration & dosage Platinum - adverse effects Point mutation Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage Poly(ADP-ribose) Polymerase Inhibitors - adverse effects Progression-Free Survival Quality of life Safety Studies Survival Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!